Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Korro Bio GalNAc-conjugated SERPINA1 RNA editing oligonucleotide
- Development stage
- Preclinical
- Lead developer
- Korro Bio
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
Korro Bio is developing a GalNAc-conjugated RNA editing oligonucleotide targeting the SERPINA1 gene for the treatment of alpha-1 antitrypsin deficiency (AATD). Utilizing the proprietary OPERA (Oligonucleotide Promoted Editing of RNA) platform, the drug is designed to recruit endogenous ADAR (Adenosine Deaminase Acting on RNA) enzymes to site-specifically edit the pathogenic G-to-A mutation in SERPINA1 mRNA transcripts. The GalNAc conjugation enables targeted delivery to hepatocytes via the asialoglycoprotein receptor (ASGPR). This approach aims to restore the production of functional alpha-1 antitrypsin protein and reduce the accumulation of misfolded protein in the liver, potentially addressing both the pulmonary and hepatic manifestations of AATD. This program is distinct from Korro Bio's KRRO-110, which utilizes lipid nanoparticle (LNP) delivery.
- Other names
- Korro Bio AATD GalNAc programGalNAc-conjugated RNA editing oligonucleotide (SERPINA1)
02
Targets
ASGPR (Asialoglycoprotein Receptor 1)Serpin family A member 1 PiZ-variant messenger RNA (SERPINA1 PiZ mRNA)ADAR (Adenosine deaminases acting on RNA (ADAR) family)SERPINA1 (Alpha-1-antitrypsin)
Beyond the preview
Go deeper on Korro Bio GalNAc-conjugated SERPINA1 RNA editing oligonucleotide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Korro Bio GalNAc-conjugated SERPINA1 RNA editing oligonucleotide.